🇺🇸 FDA
Pipeline program

AZD0516, AZD9574, AZD9574, AZD9574, AZD9574

D9520C00001

Phase 2 small_molecule active

Quick answer

AZD0516, AZD9574, AZD9574, AZD9574, AZD9574 for Metastatic Prostate Cancer is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Metastatic Prostate Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials